Outlook Therapeutics, Inc. - 8-K Filing
Outlook Therapeutics receives FDA approval for LYTENAVA™ (bevacizumab-vikg) as the first ophthalmic formulation of bevacizumab to treat wet AMD in the U.S. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $OTLK